课题基金 / 基金详情

The Establishment of KL-6 Associated New Serum Markers Using High Sensitive Electrochemiluminescence Immunoassay.

The Establishment of KL-6 Associated New Serum Markers Using High Sensitive Electrochemiluminescence Immunoassay.
使用高灵敏电化学发光免疫分析法建立 KL-6 相关新血清标志物。
批准号:
13557051
负责人:
KOHNO Nobuoki
金额:
$9.02万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003

项目摘要

项目成果

KOHNO Nobuoki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In 2003, we further improved the sensitivity of the screening method of hybridomas using M8 analyzer (IGEN Co., UK) and enabled shorter screening hours. In parallel, we repeatedly produced new hybridomas secreting monoclonal antibodies by fusing of murine myeloma cells and splenocytes from BALB/c mice previously immunized with various cancer cell lines.M8 analyzer is the machine for electrochemiluminescence immunoassay (ECLIA) applying electrochemiluminescence of Ruthenium complexes. ECLIA combined with reversed indirect sandwich assay (RISA), which we had previously established and had reported its utility, enabled approximately 1,000 times sensitivity and one sixth screening hours compared with enzyme linked immunosorbent assay (ELISA) combined with RISA (RI-ELISA).By means of this new screening method, we could have selected sixteen new multiclonal antibodies that showed strong affinity to the pooled serum obtained from lung cancer or interstitial pneumonitis patients. We tried to clone these multiclonal antibodies after exception of non-specific antibodies. Hybridomas, however, originally have weak proliferation ability and instability. These defects, therefore, induced loss of antibody secreting ability or cell death of many hybridomas in the course of cloning or freezing/thawing. Although only few monoclonal antibodies could finally be produced, some of them probably recognize different epitopes from that of original KL-6 antibody.Despite of considerable long period to establish this new screening method, we could have successfully established extremely high sensitive screening method which requires only short hours. This new method must contribute to establish new monoclonal antibodies that more sensitively and specifically react with lung cancer or interstitial pneumonitis patients' serum than original KL-6 antibody
期刊论文(65)
专著(0)
科研奖励(0)
会议论文
Shimizu Y: "Increased Plasma Ghrelin Level in Lung Cancer Cachexia"Clin Cancer Res. 9・2. 774-778 (2003)
Shimizu Y:“肺癌恶病质中血浆 Ghrelin 水平升高”《临床癌症研究》9·2(2003 年)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
河野 修興: "呼吸器疾患とKL-6(Annual Review 呼吸器 2003)"中外医学社,東京. 282 (2003)
Nobuoki Kono:“呼吸系统疾病和 KL-6(呼吸系统年度回顾 2003)”Chugai Igakusha,东京 282 (2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Katayama H: "Production of eosinophilic chemokines by normal pleural mesothelial cells"Am I Respir Cell Mol Biol. 26・4. 398-403 (2002)
Katayama H:“正常胸膜间皮细胞的嗜酸性趋化因子的产生”Am I Respir Cell Mol Biol.26·4(2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Miyazu Y: "Endobronchial ultrasonography in the diagnosis and treatment of relapsing polychondritis with tracheobronchial malacia."Chest. 124・6. 2393-2395 (2003)
Miyazu Y:“支气管内超声诊断和治疗伴有气管支气管软化症的复发性多软骨炎”124・6(2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
27
    Anti KL-6 antibody enhances the effects of molecular targeted drug
    • 批准号:
      23659433
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.25万
    • 财政年份:
      2011
    • 负责人:
      KOHNO Nobuoki
    • 依托单位:
    Comparative studies of a clinical features and genomic analysis in patients with interstitial lung disease and drug induced lung injury
    • 批准号:
      19390224
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.06万
    • 财政年份:
      2007
    • 负责人:
      KOHNO Nobuoki
    • 依托单位:
    The Study on KL-6 as Morbidity Ornamentation Factor and Prognosis Factor of Idiopathic Interstitial Pneumonia.
    • 批准号:
      14370197
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.83万
    • 财政年份:
      2002
    • 负责人:
      KOHNO Nobuoki
    • 依托单位:
    DEVELOPMENT OF A LUNG CANCER TREATMENT USING ANTI-KL-6/MUC1 MULTI-MONOCLONAL ANTIBODIES
    海外基金